PDGF upregulates Mcl-1 through activation of β-catenin and HIF-1α-dependent signaling in human prostate cancer cells

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Iqbal, Shareen ^a   Zhang, Shumin ^a   Driss, Adel ^b   Liu, Zhi Ren ^c   Kim, Hyeong Reh Choi ^d   Wang, Yanru ^a   Ritenour, Chad ^a   Zhau, Haiyen E ^e   Kucuk, Omer ^a   Chung, Leland W K ^e   Wu, Daqing ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

^c GEORGIA STATE UNIVERSITY   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BETA CATENIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN MCL 1; PROTEIN P68; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BINDING AFFINITY; CELL SURVIVAL; COMPLEX FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR PATHOLOGY; PROMOTER REGION; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; DRUG EFFECT; MALE; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; PLATELET-DERIVED GROWTH FACTOR; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 84856060485     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030764     Document Type: Article

References (54)

1. Heldin CH, Eriksson U, Ostman A, (2002) New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys 398: 284-290.
2. Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A, (2003) PDGF receptors as cancer drug targets. Cancer Cell 3: 439-443.
3. Andrae J, Gallini R, Betsholtz C, (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22: 1276-1312.
4. Kim L, Wong TW, (1995) The cytoplasmic tyrosine kinase FER is associated with the catenin-like substrate pp120 and is activated by growth factors. Mol Cell Biol 15: 4553-4561.
5. Yokote K, Margolis B, Heldin CH, Claesson-Welsh L, (1996) Grb7 is a downstream signaling component of platelet-derived growth factor alpha- and beta-receptors. J Biol Chem 271: 30942-30949.
6. Darnell JE Jr, (1997) STATs and gene regulation. Science 277: 1630-1635.
7. Yang L, Lin C, Liu ZR, (2006) P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin. Cell 127: 139-155.
8. Fischer AN, Fuchs E, Mikula M, Huber H, Beug H, et al. (2007) PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression. Oncogene 26: 3395-3405.
9. Mathew P, Thall PF, Jones D, Perez C, Bucana C, et al. (2004) Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 22: 3323-3329.
10. Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, et al. (2001) A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res 7: 800-805.
11. Hofer MD, Fecko A, Shen R, Setlur SR, Pienta KG, et al. (2004) Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia 6: 503-512.
12. Fudge K, Wang CY, Stearns ME, (1994) Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas. Mod Pathol 7: 549-554.
13. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, et al. (2002) Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1: 203-209.
14. Pietras K, Pahler J, Bergers G, Hanahan D, (2008) Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 5: e19.
15. Ostman A, Heldin CH, (2007) PDGF receptors as targets in tumor treatment. Adv Cancer Res 97: 247-274.
16. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, et al. (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62: 5476-5484.
17. Ostman A, (2004) PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15: 275-286.
18. Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, et al. (2006) Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 116: 1561-1570.
19. Kong D, Wang Z, Sarkar SH, Li Y, Banerjee S, et al. (2008) Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells 26: 1425-1435.
20. Mehlen P, Puisieux A, (2006) Metastasis: a question of life or death. Nat Rev Cancer 6: 449-458.
21. Zhang S, Zhau HE, Osunkoya AO, Iqbal S, Yang X, et al. (2010) Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer 9: 9.
22. Zhau HE, Odero-Marah V, Lue HW, Nomura T, Wang R, et al. (2008) Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis 25: 601-610.
23. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, et al. (1998) Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer 77: 887-894.
24. Akgul C, Turner PC, White MR, Edwards SW, (2000) Functional analysis of the human MCL-1 gene. Cell Mol Life Sci 57: 684-691.
25. Wu D, Zhau HE, Huang WC, Iqbal S, Habib FK, et al. (2007) cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene 26: 5070-5077.
26. Xu J, Wang R, Xie ZH, Odero-Marah V, Pathak S, et al. (2006) Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 66: 1664-1673.
27. Pienta KJ, Smith DC, (2005) Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 55: 300-318 quiz 323-305.
28. Gazit A, Yaish P, Gilon C, Levitzki A, (1989) Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem 32: 2344-2352.
29. Singh PK, Wen Y, Swanson BJ, Shanmugam K, Kazlauskas A, et al. (2007) Platelet-derived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Res 67: 5201-5210.
30. Clevers H, (2004) Wnt breakers in colon cancer. Cancer Cell 5: 5-6.
31. Wenger RH, Stiehl DP, Camenisch G, (2005) Integration of oxygen signaling at the consensus HRE. Sci STKE 2005: re12.
32. Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, et al. (2005) Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 42: 1329-1338.
33. Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, et al. (2007) The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 26: 2822-2832.
34. Langley RR, Fan D, Tsan RZ, Rebhun R, He J, et al. (2004) Activation of the platelet-derived growth factor-receptor enhances survival of murine bone endothelial cells. Cancer Res 64: 3727-3730.
35. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, et al. (2006) Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. Int J Cancer 119: 2567-2574.
36. Kodama M, Kitadai Y, Sumida T, Ohnishi M, Ohara E, et al. (2010) Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor beta is associated with lymphatic metastasis in human gastric carcinoma. Cancer Sci 101: 1984-1989.
37. Song N, Huang Y, Shi H, Yuan S, Ding Y, et al. (2009) Overexpression of platelet-derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1alpha/CXCR4 axis. Cancer Res 69: 6057-6064.
38. Yang L, Lin C, Zhao S, Wang H, Liu ZR, (2007) Phosphorylation of p68 RNA helicase plays a role in platelet-derived growth factor-induced cell proliferation by up-regulating cyclin D1 and c-Myc expression. J Biol Chem 282: 16811-16819.
39. Clark EL, Coulson A, Dalgliesh C, Rajan P, Nicol SM, et al. (2008) The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Res 68: 7938-7946.
40. Truica CI, Byers S, Gelmann EP, (2000) Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 60: 4709-4713.
41. Doble BW, Woodgett JR, (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116: 1175-1186.
42. Chesire DR, Ewing CM, Gage WR, Isaacs WB, (2002) In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 21: 2679-2694.
43. Wang JM, Chao JR, Chen W, Kuo ML, Yen JJ, et al. (1999) The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol Cell Biol 19: 6195-6206.
44. Kaidi A, Williams AC, Paraskeva C, (2007) Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 9: 210-217.
45. Chott A, Sun Z, Morganstern D, Pan J, Li T, et al. (1999) Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 155: 1271-1279.
46. George DJ, (2002) Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. Urology 60: 115-121 discussion 122.
47. Paulsson J, Sjoblom T, Micke P, Ponten F, Landberg G, et al. (2009) Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 175: 334-341.
48. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, et al. (2007) Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 13: 5816-5824.
49. Williams LT, (1989) Signal transduction by the platelet-derived growth factor receptor. Science 243: 1564-1570.
50. Rana A, Chisholm GD, Khan M, Sekharjit SS, Merrick MV, et al. (1993) Patterns of bone metastasis and their prognostic significance in patients with carcinoma of the prostate. Br J Urol 72: 933-936.
51. Roodman GD, (2004) Mechanisms of bone metastasis. N Engl J Med 350: 1655-1664.
52. Kim SJ, Uehara H, Yazici S, Langley RR, He J, et al. (2004) Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res 64: 4201-4208.
53. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, et al. (2003) Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95: 458-470.
54. Langley RR, Fidler IJ, (2007) Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 28: 297-321.